Fact CheckerSign in

NCT04833504Completed

Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

Source: ClinicalTrials.gov · Last updated 16 Jul 2025

Brief summary (registry, in English)

This study is designed to monitor all patients exposed to CD19 CAR-T expressing IL7 and CCL19 for 5 years following infusion, to assess their long-term efficacy, including the CAR-vector persistence, the normal immunity rebuilding and the risk of delayed adverse events (AEs).

Status (registry)
Completed
Study type
Observational
Enrollment
39 (actual)
First submitted
14 Dec 2020
Start date
22 Sept 2018
Primary completion date
22 Sept 2023
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
NCT number
NCT04833504

What you commit to

  • Study type: Observational
  • Participants enrolled: 39
  • From 22 Sept 2018 to the primary completion date, 22 Sept 2023
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • There are no specific exclusion criteria for this study.

Who the study is looking for

  • All patients who have received the CD19-IL7/CCL19 CAR-T therapy in the earlier enrolled clinical trail and met including and excluding criteria criteria (NCT0325847) Patients who have provided informed consent for the long term follow up study prior to their study participation .

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hui Liu
Coordinator of this site? Confirm its status		HangzhouChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.